A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma.

Trial Profile

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2012

At a glance

  • Drugs Temozolomide (Primary) ; Benzylguanine
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2012 Planned End Date changed from 1 Dec 2008 to 1 Feb 2009 as reported by ClinicalTrials.gov.
    • 13 Feb 2009 Status changed from active, no longer recruiting to discontinued, as reported by clinicaltrials.gov. AOI Pharmaceuticals decided to terminate the license agreement.
    • 04 Apr 2008 The expected estimated study completion date for this trial has changed from December 2007 to December 2008 according to ClinicalTrials.gov. The estimated final data collection date for the primary outcome measure is June 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top